Association of Genetic Variants With Myopia

NCT ID: NCT07030153

Last Updated: 2025-06-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-01

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to identify genetic factors linked to myopia, including those that influence a person's risk of developing it and how quickly it progresses (like changes in eye length). It will also examine how different treatments-such as low-dose atropine drops, orthokeratology lenses, specialized glasses, and increased outdoor time-interact with these genes. Finally, the research will develop a genetic risk score to help tailor personalized myopia prevention and treatment plans.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Genetic and myopia onset

Identify genetic variants (GWAS/WES) associated with:

* Myopia onset risk (high-risk SNPs ).
* Myopia progression rate (e.g., axial elongation/year).

Oral swab DNA analyzed for myopia-related gene variants

Intervention Type GENETIC

Beyond detecting links between gene variants and myopia development, the testing analyzes how these variants influence treatment effectiveness. The aim is to enable early risk prediction and personalized treatment guidance for children through oral DNA testing.

Genetic and myopia intervention

Evaluate gene-intervention interactions for:

* Low-dose atropine (0.01%, 0.05%).
* Orthokeratology.
* Defocus-incorporated spectacles.
* Outdoor/sunlight exposure (≥2 hours/day).

Oral swab DNA analyzed for myopia-related gene variants

Intervention Type GENETIC

Beyond detecting links between gene variants and myopia development, the testing analyzes how these variants influence treatment effectiveness. The aim is to enable early risk prediction and personalized treatment guidance for children through oral DNA testing.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral swab DNA analyzed for myopia-related gene variants

Beyond detecting links between gene variants and myopia development, the testing analyzes how these variants influence treatment effectiveness. The aim is to enable early risk prediction and personalized treatment guidance for children through oral DNA testing.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 6-18 years.
* Any Spherical equivalent refraction (SER)
* Parental consent for genetic testing.

Exclusion Criteria

* Suspected genetic syndromes (e.g., Stickler, Marfan).
* Other eye diseases (e.g., glaucoma, cataracts, retinal abnormalities, strabismus).
* Prior refractive surgery
Minimum Eligible Age

6 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing New Vision Eye Hospital

UNKNOWN

Sponsor Role collaborator

High Myopia Control Alliance (HIMALAYA)

UNKNOWN

Sponsor Role collaborator

Beijing Visionly Plus Eye Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing New Vision Eye Hospital

Beijing, , China

Site Status RECRUITING

Beijing Visionly Plus Eye Hospital

Beijing, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lin Yang, M.D.

Role: CONTACT

+86-17898805125

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lin Yang

Role: primary

+86-17898805125

Lin Yang

Role: primary

+8617898805125

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Precvision202501

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Family Myopia Study
NCT00341549 COMPLETED
Control of Myopia Using Novel Spectacle Lens Designs
NCT03623074 ACTIVE_NOT_RECRUITING NA
Novel Lenses for Myopia Progression Trial
NCT06563700 ACTIVE_NOT_RECRUITING NA
Low-Dose Atropine for Treatment of Myopia
NCT03334253 COMPLETED PHASE3